ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.254,93
0,97%
S&P 500
5.792,04
0,71%
Dow Jones
42.512,00
1,03%
Euro vs US Dollar
1,09425
-0,30%
Bitcoin
60.825,40
-2,11%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Aligos Therapeutics Inc (ALGS) Börsenkurse

Aligos Therapeutics Inc

Aligos Therapeutics Inc (ALGS)

NASDAQ
7,76
0,44
(6,01%)
Beim Schlusskurs: 10 Oktober 10:00PM
Verzögert um 15 Minuten
7,76
0,00
( 0,00% )
Nach Börsenschluss: 10:42PM
Verzögert um 15 Minuten

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
7,76
Gebot
7,75
Fragen
7,85
Volumen
31.585
7,21 Tagesbereich 7,8499
6,76 52-Wochen-Bereich 30,00
Marktkapitalisierung
24,802M
Handelsende
7,32
Handelsbeginn
7,22
Letzte Trade
657
@
7.76
Letzter Handelszeitpunkt
22:00:00
Finanzvolumen
US$ 239.923
VWAP
7,5961
Durchschnittliches Volumen (3 Mio.)
205.548
Ausgegebene Aktien
3.196.103
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,27
Gewinn pro Aktie (EPS)
-27,43
Erlöse
15,53M
Nettogewinn
-87,68M

Über Aligos Therapeutics Inc

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's p... Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.aligos.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Aligos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ALGS. The last closing price for Aligos Therapeutics was US$7,32. Over the last year, Aligos Therapeutics shares have traded in a share price range of US$ 6,76 to US$ 30,00.

Aligos Therapeutics currently has 3.196.103 shares in issue. The market capitalisation of Aligos Therapeutics is US$23,40 million. Aligos Therapeutics has a price to earnings ratio (PE ratio) of -0.27.

ALGS Neueste Nachrichten

Weitere Nachrichten

Aligos Therapeutics Appoints David Perry as Vice President of Business Development

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through...

01 Oktober 2024
GlobeNewswire Inc.

Aligos Therapeutics to Present at Investor Conferences in October

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...

30 September 2024
GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities

26 September 2024
Edgar (US Regulatory)

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through...

24 September 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH

ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat...

19 September 2024
GlobeNewswire Inc.

Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

18 September 2024
GlobeNewswire Inc.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving...

13 September 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

06 September 2024
Edgar (US Regulatory)

Form 8-K - Current report

05 September 2024
Edgar (US Regulatory)

Form 8-K - Current report

19 August 2024
Edgar (US Regulatory)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.73-8.598351001188.498.81936.76443927.81077749CS
4-6.41-45.236414961214.1716.246.7610832410.06668925CS
12-5.3025-40.593301435413.062519.56.7620554812.54725763CS
26-17.99-69.864077669925.7527.56.7628571613.81648054CS
52-11.49-59.688311688319.25306.7630730116.78066211CS
156-336.74-97.7474600871344.5449.256.7626579151.19196951CS
260-360.74-97.894165536368.5937.74756.76244451132.2654284CS

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
BLMZBloomZ Inc
US$ 1,14
(59,40%)
5,11M
TVGNTevogen Bio Holdings Inc
US$ 0,36
(38,84%)
3,02M
TRNRInteractive Strength Inc
US$ 0,163
(21,64%)
4,69M
SHPHShuttle Pharmaceuticals Holdings Inc
US$ 1,1999
(16,50%)
313
LXEHLixiang Education Holding Company Ltd
US$ 3,65
(13,35%)
444
TXG10x Genomics Inc
US$ 14,80
(-28,88%)
342,3k
CETXCemtrex Inc
US$ 0,58
(-18,31%)
3,07M
CTCXCarmell Corporation
US$ 0,3665
(-14,55%)
287,75k
MNTSMomentus Inc
US$ 0,930536
(-12,21%)
6,39M
LVROLavoro Ltd
US$ 3,61
(-9,75%)
10,26k
AGRIAgriFORCE Growing Systems Ltd
US$ 0,0679
(-0,73%)
17,13M
LCIDLucid Group Inc
US$ 3,39
(0,00%)
15,69M
MNTSMomentus Inc
US$ 0,930536
(-12,21%)
6,39M
BLMZBloomZ Inc
US$ 1,14
(59,40%)
5,11M
TRNRInteractive Strength Inc
US$ 0,163
(21,64%)
4,69M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
ALGS
Aligos Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten